Simultaneously increased TxA2 activity in isolated arterioles and platelets of rats with hyperhomocysteinemia

Zoltan Ungvari, Eszter Sarkadi-Nagy, Zsolt Bagi, Lajos Szollár, Akos Koller

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

We aimed to elucidate the effect of hyperhomocysteinemia (HHcy) on the synthesis of prostaglandins in rat skeletal muscle arterioles and platelets. Male Wistar rats were divided into 2 groups: (1) control rats, with plasma Hcy levels of 6.5±0.5 μmol/L (n=50) and (2) rats with HHcy, induced by daily intake of 1 g/kg body weight methionine in the drinking water for 4 weeks (plasma Hcy levels were 20.6±3.0 μmol/L, P<0.01 versus controls; n=50). Arterioles (diameter ≃ 130 μm) were isolated from the gracilis muscle, cannulated, and pressurized (at 80 mm Hg), and changes in their diameters were followed by video microscopy. Constrictions to bradykinin (BK; 10-10 to 10-7 mol/L) were significantly greater in HHcy than in control rat arterioles (at 10-9 mol/L BK, changes were 11±3% in control and 41±9% in HHcy rats). The cyclooxygenase inhibitor indomethacin (10-5 mol/L), the prostaglandin H2/thromboxane A2 (PGH2/TxA2) receptor antagonist SQ 29,548 (10-6 mol/L), or the TxA2 synthase inhibitor furegrelate (5X10-6 mol/L) significantly decreased constrictions to BK in both groups but more so in HHcy arterioles, thus eliminating the difference between responses of HHcy and control arterioles. Constrictions to U46619 (a TxA2 analogue) were significantly greater in HHcy than in control arterioles (at 10-8 mol/L U46619, values for controls were 33±2% and 54±3% for HHcy). Endothelium removal or indomethacin treatment attenuated constrictions to U46619 in HHcy arterioles and eliminated the difference in responses. Also, aggregation of platelets from HHcy rats to collagen and ADP was significantly enhanced compared with controls (with 5 μg/mL collagen: controls, 23±5%; HHcy, 49±5%; with 10-7 mol/L ADP: controls, 25±3%; HHcy, 35±3%). Indomethacin or SQ 29,548 caused greater inhibition of aggregation of HHcy platelets compared with controls, thereby eliminating the differences between the 2 groups. Thus, HHcy enhances TxA2 synthesis both in the arteriolar endothelium and platelets. By promoting vascular constriction and platelet aggregation simultaneously, these alterations are likely to contribute to the atherothrombotic vascular diseases described in HHcy.

Original languageEnglish (US)
Pages (from-to)1203-1208
Number of pages6
JournalArteriosclerosis, thrombosis, and vascular biology
Volume20
Issue number5
DOIs
StatePublished - Jan 1 2000
Externally publishedYes

Fingerprint

Hyperhomocysteinemia
Arterioles
Blood Platelets
Constriction
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
Platelet Aggregation
Indomethacin
Adenosine Diphosphate
Endothelium
Collagen
Prostaglandin H2 Receptors Thromboxane A2
Video Microscopy
Cyclooxygenase Inhibitors
Bradykinin
Vascular Diseases
Drinking Water
Methionine

Keywords

  • Arterioles
  • Endothelium
  • Homocysteine
  • Methionine
  • Platelet aggregation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Simultaneously increased TxA2 activity in isolated arterioles and platelets of rats with hyperhomocysteinemia. / Ungvari, Zoltan; Sarkadi-Nagy, Eszter; Bagi, Zsolt; Szollár, Lajos; Koller, Akos.

In: Arteriosclerosis, thrombosis, and vascular biology, Vol. 20, No. 5, 01.01.2000, p. 1203-1208.

Research output: Contribution to journalArticle

Ungvari, Zoltan ; Sarkadi-Nagy, Eszter ; Bagi, Zsolt ; Szollár, Lajos ; Koller, Akos. / Simultaneously increased TxA2 activity in isolated arterioles and platelets of rats with hyperhomocysteinemia. In: Arteriosclerosis, thrombosis, and vascular biology. 2000 ; Vol. 20, No. 5. pp. 1203-1208.
@article{f0fdf5f7ac974533bae2003d4446a399,
title = "Simultaneously increased TxA2 activity in isolated arterioles and platelets of rats with hyperhomocysteinemia",
abstract = "We aimed to elucidate the effect of hyperhomocysteinemia (HHcy) on the synthesis of prostaglandins in rat skeletal muscle arterioles and platelets. Male Wistar rats were divided into 2 groups: (1) control rats, with plasma Hcy levels of 6.5±0.5 μmol/L (n=50) and (2) rats with HHcy, induced by daily intake of 1 g/kg body weight methionine in the drinking water for 4 weeks (plasma Hcy levels were 20.6±3.0 μmol/L, P<0.01 versus controls; n=50). Arterioles (diameter ≃ 130 μm) were isolated from the gracilis muscle, cannulated, and pressurized (at 80 mm Hg), and changes in their diameters were followed by video microscopy. Constrictions to bradykinin (BK; 10-10 to 10-7 mol/L) were significantly greater in HHcy than in control rat arterioles (at 10-9 mol/L BK, changes were 11±3{\%} in control and 41±9{\%} in HHcy rats). The cyclooxygenase inhibitor indomethacin (10-5 mol/L), the prostaglandin H2/thromboxane A2 (PGH2/TxA2) receptor antagonist SQ 29,548 (10-6 mol/L), or the TxA2 synthase inhibitor furegrelate (5X10-6 mol/L) significantly decreased constrictions to BK in both groups but more so in HHcy arterioles, thus eliminating the difference between responses of HHcy and control arterioles. Constrictions to U46619 (a TxA2 analogue) were significantly greater in HHcy than in control arterioles (at 10-8 mol/L U46619, values for controls were 33±2{\%} and 54±3{\%} for HHcy). Endothelium removal or indomethacin treatment attenuated constrictions to U46619 in HHcy arterioles and eliminated the difference in responses. Also, aggregation of platelets from HHcy rats to collagen and ADP was significantly enhanced compared with controls (with 5 μg/mL collagen: controls, 23±5{\%}; HHcy, 49±5{\%}; with 10-7 mol/L ADP: controls, 25±3{\%}; HHcy, 35±3{\%}). Indomethacin or SQ 29,548 caused greater inhibition of aggregation of HHcy platelets compared with controls, thereby eliminating the differences between the 2 groups. Thus, HHcy enhances TxA2 synthesis both in the arteriolar endothelium and platelets. By promoting vascular constriction and platelet aggregation simultaneously, these alterations are likely to contribute to the atherothrombotic vascular diseases described in HHcy.",
keywords = "Arterioles, Endothelium, Homocysteine, Methionine, Platelet aggregation",
author = "Zoltan Ungvari and Eszter Sarkadi-Nagy and Zsolt Bagi and Lajos Szoll{\'a}r and Akos Koller",
year = "2000",
month = "1",
day = "1",
doi = "10.1161/01.ATV.20.5.1203",
language = "English (US)",
volume = "20",
pages = "1203--1208",
journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",
issn = "1079-5642",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Simultaneously increased TxA2 activity in isolated arterioles and platelets of rats with hyperhomocysteinemia

AU - Ungvari, Zoltan

AU - Sarkadi-Nagy, Eszter

AU - Bagi, Zsolt

AU - Szollár, Lajos

AU - Koller, Akos

PY - 2000/1/1

Y1 - 2000/1/1

N2 - We aimed to elucidate the effect of hyperhomocysteinemia (HHcy) on the synthesis of prostaglandins in rat skeletal muscle arterioles and platelets. Male Wistar rats were divided into 2 groups: (1) control rats, with plasma Hcy levels of 6.5±0.5 μmol/L (n=50) and (2) rats with HHcy, induced by daily intake of 1 g/kg body weight methionine in the drinking water for 4 weeks (plasma Hcy levels were 20.6±3.0 μmol/L, P<0.01 versus controls; n=50). Arterioles (diameter ≃ 130 μm) were isolated from the gracilis muscle, cannulated, and pressurized (at 80 mm Hg), and changes in their diameters were followed by video microscopy. Constrictions to bradykinin (BK; 10-10 to 10-7 mol/L) were significantly greater in HHcy than in control rat arterioles (at 10-9 mol/L BK, changes were 11±3% in control and 41±9% in HHcy rats). The cyclooxygenase inhibitor indomethacin (10-5 mol/L), the prostaglandin H2/thromboxane A2 (PGH2/TxA2) receptor antagonist SQ 29,548 (10-6 mol/L), or the TxA2 synthase inhibitor furegrelate (5X10-6 mol/L) significantly decreased constrictions to BK in both groups but more so in HHcy arterioles, thus eliminating the difference between responses of HHcy and control arterioles. Constrictions to U46619 (a TxA2 analogue) were significantly greater in HHcy than in control arterioles (at 10-8 mol/L U46619, values for controls were 33±2% and 54±3% for HHcy). Endothelium removal or indomethacin treatment attenuated constrictions to U46619 in HHcy arterioles and eliminated the difference in responses. Also, aggregation of platelets from HHcy rats to collagen and ADP was significantly enhanced compared with controls (with 5 μg/mL collagen: controls, 23±5%; HHcy, 49±5%; with 10-7 mol/L ADP: controls, 25±3%; HHcy, 35±3%). Indomethacin or SQ 29,548 caused greater inhibition of aggregation of HHcy platelets compared with controls, thereby eliminating the differences between the 2 groups. Thus, HHcy enhances TxA2 synthesis both in the arteriolar endothelium and platelets. By promoting vascular constriction and platelet aggregation simultaneously, these alterations are likely to contribute to the atherothrombotic vascular diseases described in HHcy.

AB - We aimed to elucidate the effect of hyperhomocysteinemia (HHcy) on the synthesis of prostaglandins in rat skeletal muscle arterioles and platelets. Male Wistar rats were divided into 2 groups: (1) control rats, with plasma Hcy levels of 6.5±0.5 μmol/L (n=50) and (2) rats with HHcy, induced by daily intake of 1 g/kg body weight methionine in the drinking water for 4 weeks (plasma Hcy levels were 20.6±3.0 μmol/L, P<0.01 versus controls; n=50). Arterioles (diameter ≃ 130 μm) were isolated from the gracilis muscle, cannulated, and pressurized (at 80 mm Hg), and changes in their diameters were followed by video microscopy. Constrictions to bradykinin (BK; 10-10 to 10-7 mol/L) were significantly greater in HHcy than in control rat arterioles (at 10-9 mol/L BK, changes were 11±3% in control and 41±9% in HHcy rats). The cyclooxygenase inhibitor indomethacin (10-5 mol/L), the prostaglandin H2/thromboxane A2 (PGH2/TxA2) receptor antagonist SQ 29,548 (10-6 mol/L), or the TxA2 synthase inhibitor furegrelate (5X10-6 mol/L) significantly decreased constrictions to BK in both groups but more so in HHcy arterioles, thus eliminating the difference between responses of HHcy and control arterioles. Constrictions to U46619 (a TxA2 analogue) were significantly greater in HHcy than in control arterioles (at 10-8 mol/L U46619, values for controls were 33±2% and 54±3% for HHcy). Endothelium removal or indomethacin treatment attenuated constrictions to U46619 in HHcy arterioles and eliminated the difference in responses. Also, aggregation of platelets from HHcy rats to collagen and ADP was significantly enhanced compared with controls (with 5 μg/mL collagen: controls, 23±5%; HHcy, 49±5%; with 10-7 mol/L ADP: controls, 25±3%; HHcy, 35±3%). Indomethacin or SQ 29,548 caused greater inhibition of aggregation of HHcy platelets compared with controls, thereby eliminating the differences between the 2 groups. Thus, HHcy enhances TxA2 synthesis both in the arteriolar endothelium and platelets. By promoting vascular constriction and platelet aggregation simultaneously, these alterations are likely to contribute to the atherothrombotic vascular diseases described in HHcy.

KW - Arterioles

KW - Endothelium

KW - Homocysteine

KW - Methionine

KW - Platelet aggregation

UR - http://www.scopus.com/inward/record.url?scp=0034065732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034065732&partnerID=8YFLogxK

U2 - 10.1161/01.ATV.20.5.1203

DO - 10.1161/01.ATV.20.5.1203

M3 - Article

C2 - 10807734

AN - SCOPUS:0034065732

VL - 20

SP - 1203

EP - 1208

JO - Arteriosclerosis, Thrombosis, and Vascular Biology

JF - Arteriosclerosis, Thrombosis, and Vascular Biology

SN - 1079-5642

IS - 5

ER -